Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Selective allosteric AKT1/AKT2 inhibitor

engasertib

An investigational treatment for Hereditary Hemorrhagic Telangiectasia.

Phase 3by Vaderis Therapeutics
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Drug facts

The same compound appears under different names depending on the context. Here is how to identify engasertib wherever you encounter it, plus the key facts at a glance.

Generic name
engasertib
Development code
VAD044
Drug class
Selective allosteric AKT1/AKT2 inhibitor
Manufacturer
Vaderis Therapeutics
How it's taken
Capsule by mouth once a day, in a trial only

An investigational once-daily pill from Vaderis Therapeutics, a Swiss company, designed to block AKT1 and AKT2, enzymes that pass on growth signals inside the cells that line blood vessels[6][8].

  • Engasertib, first called VAD044, is being tested for hereditary hemorrhagic telangiectasia (HHT) in a Phase 3 trial (NCT07743671) that compares it with a placebo and counts nosebleeds over 28 weeks[1].
  • A 12-week proof-of-concept study in 75 adults, published in the New England Journal of Medicine in November 2025, was designed mainly to check safety[4].
  • Vaderis says engasertib has not been approved in any country for any use[6].
Follow engasertib by email

We'll email you when the FDA acts on engasertib and when new trials for Hereditary Hemorrhagic Telangiectasia open. Unsubscribe anytime.

You'll get, for Hereditary Hemorrhagic Telangiectasia:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

Where engasertib fits

Engasertib is an experimental once-daily pill from Vaderis Therapeutics, designed to block the AKT1 and AKT2 enzymes, now in a Phase 3 trial for nosebleeds in adults with moderate to severe hereditary hemorrhagic telangiectasia (HHT)[1][6].

  • No treatment for HHT is approved by the FDA or the European Medicines Agency, the PATH-HHT researchers wrote in the New England Journal of Medicine in 2024[9].
  • Bleeding care in HHT relies on procedures that seal fragile vessels in the nose and gut, antifibrinolytic drugs such as tranexamic acid used off label, and sometimes surgery, according to the same paper[9].
  • The Second International HHT Guidelines, published in 2020 in the Annals of Internal Medicine, give recommendations on nosebleeds, gut bleeding, and anemia and iron deficiency[10].
  • In the PATH-HHT trial of 144 people, pomalidomide lowered nosebleed severity more than placebo over 24 weeks, and smaller studies have tested bevacizumab and thalidomide[9].
  • Engasertib has been compared only with a placebo, and ClinicalTrials.gov lists no study comparing engasertib with pomalidomide, bevacizumab, tranexamic acid or any other HHT treatment[1][4].
  • The engasertib Phase 3 trial excludes recent use of several blood vessel drugs, so a question to bring to an HHT specialist is whether a person's current medicines and nosebleed history would fit the trial[1].

How engasertib works

In HHT, some arteries connect straight into veins without the tiny capillaries that normally sit between them. These connections are called arteriovenous malformations, and the small ones near the surface of the skin, visible as red marks, are called telangiectases[11]. Changes in several genes, including ENG, ACVRL1 and SMAD4, cause HHT, according to MedlinePlus Genetics[11].

The ACVRL1 gene makes a receptor called ALK1 on blood vessel lining cells. In a 2016 study in mice, researchers found that switching off ALK1 raised signaling through a pathway called PI3K/AKT, and that a drug blocking PI3K prevented malformed vessels from forming and reversed ones already present[8]. That work was done in animals, not people.

Engasertib aims at the next step in that same pathway. Vaderis describes it as an oral selective allosteric inhibitor of AKT1 and AKT2, meaning it attaches to the enzymes away from their main working site and turns them down[6]. Whether calming this signal reduces nosebleeds in people with HHT is what the Phase 3 trial is testing[1].

Clinical trial results

The Phase 3 trial (NCT07743671, sponsor code HHT-301) plans to enroll about 240 adults with moderate to severe HHT and assigns them by chance to engasertib 40mg or a placebo once a day for 28 weeks, with neither participants nor their doctors knowing which[1]. Its main measure is the total number of nosebleeds from day 1 through week 28[1].

Other measures at week 28 include nosebleed duration, the Epistaxis Severity Score, the NOSE HHT questionnaire on how nosebleeds affect daily life, red blood cell transfusions, an HHT quality of life score and how much better people feel their nosebleeds are[1]. ClinicalTrials.gov lists the trial's actual start as November 2, 2026 and an estimated primary completion of June 2028[1].

On August 11, 2026 Vaderis announced the start of HEROIC, a global, randomized, double-blind, placebo-controlled Phase 3 study of once-daily engasertib in moderate to severe HHT, with sites planned in North America, South America and Europe; the release does not give a ClinicalTrials.gov number[6].

The proof-of-concept study (NCT05406362) randomly assigned 75 adults to engasertib 30mg (24 people), 40mg (25 people) or placebo (26 people) once a day for 12 weeks[4]. Its main measures were the frequency and severity of side effects, and nosebleed frequency and duration were secondary measures[4]. From the start to week 12, the paper reports an average drop in nosebleed frequency of 26.5% with 30mg, 27.8% with 40mg and 18.0% with placebo, and an average drop in nosebleed duration of 29.9%, 41.4% and 23.8%[4].

The authors wrote that engasertib was associated with decreases in nosebleed frequency and duration[4]. Vaderis reported that 61% of people on 40mg rated themselves much better, against 27% on placebo[5]. The study was small, and the Phase 3 trial is meant to test whether these early findings hold up[6].

People who finished the 12 weeks could join an open-label extension, with no placebo group, lasting up to 36 months[2]. Vaderis reported in December 2025 that over 12 months of further treatment in that extension, average bleeding duration fell by 66% and average bleeding frequency by 55%[5]. ClinicalTrials.gov lists the study as active but not recruiting, with an estimated completion of January 2027[2].

Main registered trial: NCT07743671 on ClinicalTrials.gov. Check it for the current status, sites and contacts before asking about enrollment.

Side effects and safety

Early trial safety observations

In the proof-of-concept study, the most common side effects linked to engasertib were rash and high blood sugar (hyperglycemia), both mild to moderate and reversible, according to the published paper[4]. Rash occurred in 5 of the people on 30mg (21%), 10 on 40mg (42%) and 2 on placebo (8%)[4]. High blood sugar occurred in 3 people on 40mg (12%) and in no one in the other 2 groups[4].

Serious side effects were about as common in each engasertib group as on placebo, and the rash went away in most people who kept taking the drug[4]. Vaderis describes rash and high blood sugar as typical for drugs that work this way[5]. That study left out people with type 1 diabetes or uncontrolled type 2 diabetes, and the Phase 3 trial leaves out people with a history or current diagnosis of clinically significant ECG abnormalities or significant or uncontrolled skin disorders[2][1].

Vaderis also ran a study in 27 healthy adults on how itraconazole, a medicine that blocks a drug-carrying protein called P-glycoprotein, changes engasertib levels in the blood; it ended on October 28, 2026 and its results have not been posted[3].

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking engasertib

Taken by mouth as a capsule once a day, in trials only[1]. The Phase 3 trial gives 40mg once a day or a matching placebo for 28 weeks[1]. The proof-of-concept study tested 30mg and 40mg once a day for 12 weeks[2]. In its open-label extension, everyone started at 30mg once a day for 4 weeks, after which the dose could rise to 40mg, for up to 36 months[2]. Any approved dose would be set by an FDA label.

Development history

The proof-of-concept study was first posted on ClinicalTrials.gov in June 2022, and it began on July 18, 2022[2]. On November 17, 2024 Vaderis announced that the FDA had given VAD044 Fast Track designation for HHT, a program meant to speed the development and review of drugs for serious conditions[7]. The New England Journal of Medicine published the proof-of-concept results in its November 27, 2025 issue, and Vaderis announced the publication and its extension results on December 2, 2025[4][5].

On August 11, 2026 Vaderis announced a $152 million Series B financing and the start of the Phase 3 HEROIC study[6]. The Phase 3 trial NCT07743671 was first posted on ClinicalTrials.gov on August 4, 2026, and the registry lists its start as November 2, 2026[1].

Ask anything about engasertib
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Start withor ask

Explore Hereditary Hemorrhagic Telangiectasia trials

Other Hereditary Hemorrhagic Telangiectasia treatments

Common questions about engasertib

▸What is engasertib?

An investigational once-daily pill from Vaderis Therapeutics, a Swiss company, designed to block AKT1 and AKT2, enzymes that pass on growth signals inside the cells that line blood vessels[6][8]. Engasertib, first called VAD044, is being tested for hereditary hemorrhagic telangiectasia (HHT) in a Phase 3 trial (NCT07743671) that compares it with a placebo and counts nosebleeds over 28 weeks[1]. A 12-week proof-of-concept study in 75 adults, published in the New England Journal of Medicine in November 2025, was designed mainly to check safety[4]. Vaderis says engasertib has not been approved in any country for any use[6].

▸How does engasertib work?

In HHT, some arteries connect straight into veins without the tiny capillaries that normally sit between them. These connections are called arteriovenous malformations, and the small ones near the surface of the skin, visible as red marks, are called telangiectases[11]. Changes in several genes, including ENG, ACVRL1 and SMAD4, cause HHT, according to MedlinePlus Genetics[11].

The ACVRL1 gene makes a receptor called ALK1 on blood vessel lining cells. In a 2016 study in mice, researchers found that switching off ALK1 raised signaling through a pathway called PI3K/AKT, and that a drug blocking PI3K prevented malformed vessels from forming and reversed ones already present[8]. That work was done in animals, not people.

Engasertib aims at the next step in that same pathway. Vaderis describes it as an oral selective allosteric inhibitor of AKT1 and AKT2, meaning it attaches to the enzymes away from their main working site and turns them down[6]. Whether calming this signal reduces nosebleeds in people with HHT is what the Phase 3 trial is testing[1].

▸What are the side effects of engasertib?

In the proof-of-concept study, the most common side effects linked to engasertib were rash and high blood sugar (hyperglycemia), both mild to moderate and reversible, according to the published paper[4]. Rash occurred in 5 of the people on 30mg (21%), 10 on 40mg (42%) and 2 on placebo (8%)[4]. High blood sugar occurred in 3 people on 40mg (12%) and in no one in the other 2 groups[4]. Serious side effects were about as common in each engasertib group as on placebo, and the rash went away in most people who kept taking the drug[4]. Vaderis describes rash and high blood sugar as typical for drugs that work this way[5]. That study left out people with type 1 diabetes or uncontrolled type 2 diabetes, and the Phase 3 trial leaves out people with a history or current diagnosis of clinically significant ECG abnormalities or significant or uncontrolled skin disorders[2][1]. Vaderis also ran a study in 27 healthy adults on how itraconazole, a medicine that blocks a drug-carrying protein called P-glycoprotein, changes engasertib levels in the blood; it ended on October 28, 2026 and its results have not been posted[3].

▸How is engasertib taken?

Taken by mouth as a capsule once a day, in trials only[1]. The Phase 3 trial gives 40mg once a day or a matching placebo for 28 weeks[1]. The proof-of-concept study tested 30mg and 40mg once a day for 12 weeks[2]. In its open-label extension, everyone started at 30mg once a day for 4 weeks, after which the dose could rise to 40mg, for up to 36 months[2]. Any approved dose would be set by an FDA label.

▸Is engasertib FDA approved?

engasertib is currently in phase 3 clinical trials for Hereditary Hemorrhagic Telangiectasia. It has not yet received FDA approval.

▸Is engasertib FDA approved for HHT?

No. Engasertib is an experimental pill in a Phase 3 trial for hereditary hemorrhagic telangiectasia, and Vaderis says it has not been approved in any country for any use.

Maker: Vaderis Therapeutics.

Other name: VAD044.

FDA status: Fast Track designation for HHT, announced by Vaderis on November 17, 2024.

Source: Vaderis, August 11, 2026 and Vaderis, November 17, 2024

▸What did the engasertib proof-of-concept study show?

In 75 adults over 12 weeks, the published paper reports average drops in nosebleed frequency of 26.5% on 30mg, 27.8% on 40mg and 18.0% on placebo.

Duration: Average drops of 29.9%, 41.4% and 23.8%.

Design: The main measures were side effects; nosebleeds were secondary measures.

Common side effects: Mild to moderate rash and high blood sugar, both reversible.

Source: Al-Samkari et al., NEJM 2025

▸Who can join the engasertib Phase 3 trial?

Adults 18 and older with a definite HHT diagnosis, an Epistaxis Severity Score above 4 and regular nosebleeds.

Blood count rule: Anemia, or an iron infusion of at least 250mg or a transfusion in the past 6 months.

Not eligible: Recent nasal cauterization or surgery, or use of drugs such as bevacizumab, pomalidomide, thalidomide or sirolimus within 6 weeks.

US sites: Gainesville, Chicago, Indianapolis, Rochester (Minnesota), St. Louis and Salt Lake City.

Source: ClinicalTrials.gov NCT07743671

▸When will engasertib Phase 3 results come out?

Vaderis has not given a date. ClinicalTrials.gov lists an estimated primary completion of June 2028.

What is measured: The total number of nosebleeds over 28 weeks, engasertib 40mg against a placebo.

Size: About 240 adults.

Source: ClinicalTrials.gov NCT07743671

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

  1. ClinicalTrials.gov. A Trial to Assess the Efficacy and Safety of Engasertib in Participants With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT). https://clinicaltrials.gov/study/NCT07743671
  2. ClinicalTrials.gov. Assess Safety and Efficacy of VAD044 in HHT Patients. https://clinicaltrials.gov/study/NCT05406362
  3. ClinicalTrials.gov. Effect of a Known P-glycoprotein (P-gp) Inhibitor, Itraconazole, on the Pharmacokinetics (PK) of Engasertib. https://clinicaltrials.gov/study/NCT07800429
  4. New England Journal of Medicine · 2025-11-27. Engasertib versus Placebo for Bleeding in Hereditary Hemorrhagic Telangiectasia. https://pubmed.ncbi.nlm.nih.gov/41297007/
  5. Vaderis Therapeutics · 2025-12-02. Vaderis Therapeutics Announces The New England Journal of Medicine Publishes Engasertib Proof-of-Concept and Long-Term Extension Results. https://vaderis.com/vaderis-therapeutics-announces-the-new-england-journal-of-medicine-publishes-engasertib-proof-of-concept-and-long-term-extension-results-2/
  6. Vaderis Therapeutics · 2026-08-11. Vaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic Telangiectasia. https://vaderis.com/vaderis-therapeutics-announces-oversubscribed-financing-and-initiation-of-the-global-phase-3-study/
  7. Vaderis Therapeutics · 2024-11-17. Vaderis Receives FDA Fast Track Designation for VAD044 for the Treatment of Hereditary Hemorrhagic Telangiectasia. https://vaderis.com/fda-fast-track-designation-for-vad044/
  8. Nature Communications · 2016-11-29. PI3 kinase inhibition improves vascular malformations in mouse models of hereditary haemorrhagic telangiectasia. https://pubmed.ncbi.nlm.nih.gov/27897192/
  9. New England Journal of Medicine · 2024-09-19. Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia. https://pubmed.ncbi.nlm.nih.gov/39292928/
  10. Annals of Internal Medicine · 2020-12-15. Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. https://pubmed.ncbi.nlm.nih.gov/32894695/
  11. MedlinePlus, National Library of Medicine. Hereditary hemorrhagic telangiectasia. https://medlineplus.gov/genetics/condition/hereditary-hemorrhagic-telangiectasia/

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: November 2026.

Follow engasertib by email

We'll email you when the FDA acts on engasertib and when new trials for Hereditary Hemorrhagic Telangiectasia open. Unsubscribe anytime.

You'll get, for Hereditary Hemorrhagic Telangiectasia:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site